Sequencing systemic therapies in metastatic castration-resistant prostate cancer.
about
Dynamic regulation of Rad51 by E2F1 and p53 in prostate cancer cells upon drug-induced DNA damage under hypoxiaPoly (ADP-ribose) polymerase inhibitor: an evolving paradigm in the treatment of prostate cancer.Synergistic simvastatin and metformin combination chemotherapy for osseous metastatic castration-resistant prostate cancer.Comparative analysis of the effectiveness of abiraterone before and after docetaxel in patients with metastatic castration-resistant prostate cancer.Embelin, a small molecule quinone with a co-clinical power for castrate-resistant prostate cancer.Identification of simvastatin-regulated targets associated with JNK activation in DU145 human prostate cancer cell death signaling.
P2860
Sequencing systemic therapies in metastatic castration-resistant prostate cancer.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Sequencing systemic therapies in metastatic castration-resistant prostate cancer.
@en
type
label
Sequencing systemic therapies in metastatic castration-resistant prostate cancer.
@en
prefLabel
Sequencing systemic therapies in metastatic castration-resistant prostate cancer.
@en
P2860
P1433
P1476
Sequencing systemic therapies in metastatic castration-resistant prostate cancer.
@en
P2093
Jane Jijun Liu
Jingsong Zhang
P2860
P304
P356
10.1177/107327481302000306
P577
2013-07-01T00:00:00Z